Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma

References

• Gershenwald JE, Guy GP Jr. Stemming the rising incidence of melanoma: calling prevention to action. J Natl Cancer Inst. 2016;108(1). doi:10.1093/jnci/djv381
   Google Scholar
• Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52(4):1071–1080. doi:10.3892/ijo.2018.4287
   PubMed Web of Science ®Google Scholar
• Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am. 2020;100(1):1–12. doi:10.1016/j.suc.2019.09.005
   PubMed Web of Science ®Google Scholar
• Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–250. doi:10.1016/j.semcancer.2019.08.002
   PubMed Web of Science ®Google Scholar
• Queirolo P, Boutros A, Tanda E, Spagnolo F, Quaglino P. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol. 2019;59:290–297. doi:10.1016/j.semcancer.2019.08.001
   PubMed Web of Science ®Google Scholar
• Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366–1379. doi:10.1080/15384047.2019.1640032
   PubMed Web of Science ®Google Scholar
• Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–68. doi:10.1016/j.canlet.2016.01.043
   PubMed Web of Science ®Google Scholar
• Attrill GH, Ferguson PM, Palendira U, Long GV, Wilmott JS, Scolyer RA. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res. 2021;34(3):529–549. doi:10.1111/pcmr.12926
   PubMed Web of Science ®Google Scholar
• Attrill GH, Ferguson PM, Palendira U, Long GV, Wilmott JS, Scolyer RA. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res. 2020. doi:10.1111/pcmr.12926
   PubMed Web of Science ®Google Scholar
• Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407. doi:10.1016/j.cell.2018.01.011
   PubMed Web of Science ®Google Scholar
• Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–669. doi:10.1534/genetics.112.146704
   PubMed Web of Science ®Google Scholar
• Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–719. doi:10.4161/rna.20481
   PubMed Web of Science ®Google Scholar
• Leucci E, Coe EA, Marine JC, Vance KW. The emerging role of long non-coding RNAs in cutaneous melanoma. Pigment Cell Melanoma Res. 2016;29(6):619–626. doi:10.1111/pcmr.12537
   PubMed Web of Science ®Google Scholar
• Luan W, Ding Y, Ma S, Ruan H, Wang J, Lu F. Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis. Cell Death Dis. 2019;10(11):855. doi:10.1038/s41419-019-2090-3
   PubMed Web of Science ®Google Scholar
• Wei X, Gu X, Ma M, Lou C. Long noncoding RNA HCP5 suppresses skin cutaneous melanoma development by regulating RARRES3 gene expression via sponging miR-12. Onco Targets Ther. 2019;12:6323–6335. doi:10.2147/OTT.S195796
   PubMed Web of Science ®Google Scholar
• Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962–972. doi:10.1038/ni.3771
   PubMed Web of Science ®Google Scholar
• Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017;35:177–198. doi:10.1146/annurev-immunol-041015-055459
   PubMed Web of Science ®Google Scholar
• Mowel WK, Kotzin JJ, McCright SJ, Neal VD, Henao-Mejia J. Control of immune cell homeostasis and function by lncRNAs. Trends Immunol. 2018;39(1):55–69. doi:10.1016/j.it.2017.08.009
   PubMed Web of Science ®Google Scholar
• Sang LJ, Ju HQ, Liu GP, et al. LncRNA CamK-A regulates Ca(2+)-signaling-mediated tumor microenvironment remodeling. Mol Cell. 2018;72(1):71–83e7. doi:10.1016/j.molcel.2018.08.014
   PubMed Web of Science ®Google Scholar
• Sun J, Zhang Z, Bao S, et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8(1):e000110. doi:10.1136/jitc-2019-000110
   PubMed Web of Science ®Google Scholar
• Hong W, Liang L, Gu Y, et al. Immune-related lncRNA to construct novel signature and predict the immune landscape of human hepatocellular carcinoma. Mol Ther Nucleic Acids. 2020;22:937–947. doi:10.1016/j.omtn.2020.10.002
   PubMedGoogle Scholar
• Wick MR. Cutaneous melanoma: a current overview. Semin Diagn Pathol. 2016;33(4):225–241. doi:10.1053/j.semdp.2016.04.007
   PubMed Web of Science ®Google Scholar
• Hyams DM, Cook RW, Buzaid AC. Identification of risk in cutaneous melanoma patients: prognostic and predictive markers. J Surg Oncol. 2019;119(2):175–186. doi:10.1002/jso.25319
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Wittig JA. Principles of immunotherapy in melanoma. Surg Clin North Am. 2020;100(1):161–173. doi:10.1016/j.suc.2019.09.009
   PubMed Web of Science ®Google Scholar
• Dowling J, McGregor SP, Williford P. Update on current treatment recommendations for primary cutaneous melanoma. Dermatol Clin. 2019;37(4):397–407. doi:10.1016/j.det.2019.06.001
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; Committee EG. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126–32. doi:10.1093/annonc/mdv297
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7–13. doi:10.1016/j.canlet.2015.07.039
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232(2):199–209. doi:10.1002/path.4287
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X
   PubMed Web of Science ®Google Scholar
• Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):Sep. doi:10.3390/cells8091015
   Web of Science ®Google Scholar
• Shen Y, Peng X, Shen C. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112(3):2640–2646. doi:10.1016/j.ygeno.2020.02.015
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Xu Y, Wu X, Zhou Y, Mo J. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol. 2020;235(12):9304–9316. doi:10.1002/jcp.29730
   PubMed Web of Science ®Google Scholar
• Li Z, Wang D, Yin H. A seven immune-related lncRNA signature predicts the survival of patients with colon adenocarcinoma. Am J Transl Res. 2020;12(11):7060–7078.
   PubMed Web of Science ®Google Scholar
• Jin D, Song Y, Chen Y, Zhang P. Identification of a seven-lncRNA immune risk signature and construction of a predictive nomogram for lung adenocarcinoma. Biomed Res Int. 2020;2020:7929132. doi:10.1155/2020/7929132
   PubMed Web of Science ®Google Scholar
• Liu N, Liu Z, Liu X, Chen H. Comprehensive analysis of a competing endogenous RNA network identifies seven-lncRNA signature as a prognostic biomarker for melanoma. Front Oncol. 2019;9:935. doi:10.3389/fonc.2019.00935
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Valenti F, Sacconi A, et al. Long non-coding MIR205HG depletes Hsa-miR-590-3p leading to unrestrained proliferation in head and neck squamous cell carcinoma. Theranostics. 2018;8(7):1850–1868. doi:10.7150/thno.22167
   PubMed Web of Science ®Google Scholar
• Guo J, Gan Q, Gan C, Zhang X, Ma X, Dong M. LncRNA MIR205HG regulates melanomagenesis via the miR-299-3p/VEGFA axis. Aging (Albany NY). 2021;12. doi:10.18632/aging.202450.
   PubMedGoogle Scholar
• Sun Z, Jing C, Xiao C, Li T. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients. Aging (Albany NY). 2020;12(15):15624–15637. doi:10.18632/aging.103718
   PubMedGoogle Scholar
• Meng C, Zhou JQ, Liao YS. Autophagy-related long non-coding RNA signature for ovarian cancer. J Int Med Res. 2020;48(11):300060520970761. doi:10.1177/0300060520970761
   PubMed Web of Science ®Google Scholar
• Chen P, Gao Y, Ouyang S, et al. A prognostic model based on immune-related long non-coding RNAs for patients with cervical cancer. Front Pharmacol. 2020;11:585255. doi:10.3389/fphar.2020.585255
   PubMed Web of Science ®Google Scholar
• Ohadian Moghadam S, Nowroozi MR. Toll-like receptors: the role in bladder cancer development, progression and immunotherapy. Scand J Immunol. 2019;90(6):e12818. doi:10.1111/sji.12818
   PubMed Web of Science ®Google Scholar
• Bourquin C, Pommier A, Hotz C. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2020;154:104192. doi:10.1016/j.phrs.2019.03.001
   PubMed Web of Science ®Google Scholar
• Groner B, von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451:1–14. doi:10.1016/j.mce.2017.05.033
   PubMed Web of Science ®Google Scholar
• Olbryt M, Rajczykowski M, Widlak W. Biological factors behind melanoma response to immune checkpoint inhibitors. Int J Mol Sci. 2020;21(11):4071. doi:10.3390/ijms21114071
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Li H, van der Leun AM, Yofe I, et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 2019;176(4):775–789e18. doi:10.1016/j.cell.2018.11.043
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Borst J, Ahrends T, Babala N, Melief CJM, Kastenmuller W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635–647. doi:10.1038/s41577-018-0044-0
   PubMed Web of Science ®Google Scholar
• Wang H, Yang L, Wang D, Zhang Q, Zhang L. Pro-tumor activities of macrophages in the progression of melanoma. Hum Vaccin Immunother. 2017;13(7):1556–1562. doi:10.1080/21645515.2017.1312043
   PubMed Web of Science ®Google Scholar
• Choo YW, Kang M, Kim HY, et al. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitor. ACS Nano. 2018;12(9):8977–8993. doi:10.1021/acsnano.8b02446
   PubMed Web of Science ®Google Scholar